Halozyme Therapeutics (HALO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 May, 2026Opening remarks and agenda
Meeting called to order with voting and Q&A instructions provided to shareholders.
Mark Snyder appointed as secretary and Inspector of Elections; board members and auditors introduced.
Quorum established with 104.1 million shares represented, authorizing business transactions.
Agenda included election of two Class I directors, advisory vote on executive compensation, and ratification of the auditor.
Board and executive committee updates
Bernadette Connaughton and Matthew Posard elected as Class I directors for a three-year term.
Special thanks extended to outgoing board member Moni Miyashita for her contributions.
Shareholder proposals
Advisory vote approved executive compensation.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Latest events from Halozyme Therapeutics
- Strong royalty-driven growth and durable revenues supported by innovation and global adoption.HALO
Morgan Stanley 23rd Annual Global Healthcare Conference9 Jul 2026 - 2026 guidance raised and three SC platforms added, projecting over $2B revenue by 2028.HALO
Investor update8 Jul 2026 - Licensing talks with Merck on subcutaneous Keytruda may yield major royalties; litigation possible if unresolved.HALO
TD Cowen 45th Annual Healthcare Conference8 Jul 2026 - Royalty projections remain intact through 2032, with new MDASE patents broadening licensing options.HALO
Investor Update8 Jul 2026 - Q1 2025 revenue up 35%, guidance raised, and $250M share repurchase announced.HALO
Q1 20258 Jul 2026 - Q1 2026 revenue up 42%, strong royalties, new deals, and $1B buyback announced.HALO
Q1 202611 May 2026 - Director elections, executive pay, and auditor ratification headline the May 2026 meeting.HALO
Proxy filing23 Mar 2026 - 2026 proxy covers director elections, say-on-pay, auditor ratification, and record 2025 performance.HALO
Proxy filing23 Mar 2026 - Strong royalty-driven growth, pipeline expansion, and new technologies fuel long-term outlook.HALO
The Citizens Life Sciences Conference 202611 Mar 2026